Predictive models for hepatocellular carcinoma (HCC) have been limited by modest accuracy and lack of validation. Machine-learning algorithms offer a novel methodology, which may improve HCC risk prognostication among patients with cirrhosis. Our study ' s aim was to develop and compare predictive models for HCC development among cirrhotic patients, using conventional regression analysis and machine-learning algorithms.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third leading cause of cancerrelated death worldwide and one of the leading causes of death among patients with cirrhosis. Its incidence in the United States is increasing due to the current epidemic of hepatitis C virus infection and non-alcoholic fatty liver disease ( 1 ) . Prognosis for patients with HCC depends on tumor stage, with curative options available for patients diagnosed at an early stage ( 2 ) . Patients with early HCC achieve 5-year survival rates of 70 % with resection or transplantation, whereas those with advanced HCC have a median survival of < 1 year ( 3, 4 ) . Surveillance using ultrasound with or without alpha fetoprotein (AFP) every 6 months strives to detect HCC at an early stage when it is amenable to curative therapy ( 5 ) and is recommended in highrisk populations ( 6 ) . One of the central criteria for an eff ective surveillance program is the accurate identifi cation of a high-risk target population. Patients with cirrhosis are at particularly high risk for developing HCC, with an annual risk of developing HCC between 2 and 7 % , although this may not be uniform across all patients and etiologies of liver disease ( 7 ) . Identifi cation of other risk factors among patients with cirrhosis may defi ne a subgroup of high-risk patients in whom surveillance could be targeted.
Retrospective case-control studies have identifi ed risk factors for HCC among patients with cirrhosis, including older age, male gender, diabetes, and alcohol intake ( 7 ) . Subsequent studies have developed predictive models for the development of HCC using several of these risk factors, although they are limited by moderate accuracy and none have been validated in independent cohorts. Machine learning is a novel form of artifi cial intelligence that has been previously used to predict behavior or outcomes in business, such as identifying consumer preferences for products based on prior purchasing history or web-surfers affi nity to particular advertisements based on mouse-click history. Machine-learning algorithms have several advantages over traditional statistical modeling, including the ability to recognize clinically important risk among patients with several marginal risk factors and continually incorporate new clinical data with minimal oversight ( Supplementary Material online) ( 8 ) . It has been successfully used in medicine to identify factors associated with treatment response in hepatitis C virus patients and response to resection among patients with HCC ( 9,10 ), but its benefi t in HCC risk estimation has yet to be fully explored. Th e aims of our study were to develop and compare predictive models using conventional regression analysis and machine-learning algorithms.
METHODS

University of Michigan study population (UM Cohort) and follow-up
Between January 2004 and September 2006, consecutive patients with cirrhosis but no detectable HCC were prospectively identifi ed and entered into a surveillance program using ultrasound and AFP, as has been previously described in detail ( 11 ) . Patients were enrolled from Hepatology and Transplant Hepatology clinics at the University of Michigan if they had Child-Pugh class A or B cirrhosis and absence of known HCC at the time of initial evaluation. Patients diagnosed with HCC within the fi rst 6 months of enrollment (i.e. four patients with prevalent cases) were excluded. Other exclusion criteria included clinical evidence of signifi cant hepatic decompensation (refractory ascites, grade 3 -4 encephalopathy, active variceal bleeding, or hepatorenal syndrome), comorbid medical conditions with a life expectancy of < 1 year, prior solid organ transplant, and a known extrahepatic primary tumor. Th is study protocol was approved by the Institutional Review Board at the University of Michigan, and informed consent was obtained in writing from each patient.
Th e following demographic and clinical data were collected at the time of enrollment: age, gender, race, body mass index, past medical history, lifetime alcohol use, and lifetime tobacco use. Data regarding their liver disease included the underlying etiology and presence of ascites, encephalopathy, or esophageal varices. Laboratory data of interest at the time of enrollment included: platelet count, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin, albumin, international normalized ratio, and AFP. Patients underwent prospective evaluation every 6 -12 months by physical examination, ultrasound, and AFP. If an AFP level was > 20 ng / ml or any mass lesion was seen on ultrasound, triple-phase computed tomography or magnetic resonance imaging was performed to further evaluate the presence of HCC. Patients were followed until the time of HCC diagnosis, liver transplantation, death, or until the study was terminated on 31 July 2010.
HCC was diagnosed using the American Association for the Study of Liver Disease guidelines at the time of the study, and the Barcelona Clinic Liver Cancer (BCLC) system was used for tumor staging ( 6 ) . For tumors > 2 cm in size, the diagnosis was made by the presence of a typical vascular pattern on dynamic imaging (arterial enhancement and washout on delayed images) or an AFP > 200 ng / ml. For tumors with a maximum diameter of 1 -2 cm, the diagnosis was made by the presence of a typical vascular pattern on two dynamic imaging studies or histology. All HCC diagnoses were adjudicated by two authors (A.S. and J.M.) to confi rm that they met diagnostic criteria and to determine tumor stage at the time of diagnosis.
Development of regression model
We developed a predictive regression model for the development of HCC using the University of Michigan (UM) cohort. Th e relationship of patient factors to HCC development was assessed by Wilcoxon rank sum tests, χ 2 -tests, and univariate Cox regression. All parameters with a P < 0.10 in univariate analysis, as well as those determined to be clinically relevant a priori (age, gender, body mass index, diabetes, viral etiology, and Child Pugh class), were selected for the multivariate Cox regression model, in which a P < 0.05 was considered signifi cant.
Development of machine-learning algorithm models
We also used random forest analysis ( 12, 13 ) , a type of machinelearning algorithm that can build classifi cation prediction models, to identify baseline risk factors associated with the development of HCC in the UM cohort. Th e random forest approach divides the initial cohort into two groups -" in-bag " and " out-of-bag " samples. Th e in-bag sample is created using random sampling with replacement from the initial cohort, creating a sample equivalent in size to the initial cohort. Th e out-of-bag sample is composed of the unsampled data from the initial cohort, and typically includes about one-third of the initial cohort. Th is process is repeated 500 times to create multiple pairings of in-bag and outof-bag samples. For each pairing, a decision tree ( Supplementary Figure ) is constructed on the in-bag sample, using a random set of potential candidate variables for each split, and then validated using the out-of-bag sample. As each tree is built, only a random subset of the predictor variables is considered as possible splitters for each binary partitioning. Th e predictions from each tree are used as " votes " , and the outcome with the most votes is considered The American Journal of GASTROENTEROLOGY the dichotomous outcome prediction for that sample. Using this method, multiple decision trees are constructed to create the fi nal classifi cation prediction model and determine overall variable importance. Accuracies and error rates are computed for each observation using the out-of-bag predictions, and then averaged over all observations. Because the out-of-bag observations were not used in the fi tting of the trees, the out-of-bag estimates serve as cross-validated accuracy estimates. Variable importance identifi es the most important variables based on their contribution to the predictive accuracy of the model ( 14 ). Th e most important variables are identifi ed as those that most frequently result in early splitting of the decision trees. Th e fi nal algorithms, consisting of 500 trees each, are not presented here for the sake of brevity.
HALT-C trial study population (HALT-C cohort) and follow-up
Th e regression model and machine-learning algorithm were externally validated using data from the Hepatitis C Antiviral Longterm Treatment against Cirrhosis (HALT-C) Trial. Th e design of HALT-C, including the surveillance protocol, has been previously described in detail ( 15 -17 ) . In brief, patients were included if they had chronic hepatitis C virus infection with advanced fi brosis or cirrhosis (Ishak score ≥ 3) without decompensation and had failed to achieve sustained virologic response aft er previous interferon treatment. Aft er 24 weeks of pegylated interferon and ribavirin, those who remained viremic at week 20 were randomized to pegylated interferon maintenance therapy or no further therapy for the next 3.5 years. Aft er the initial 3.5 years of follow-up, patients were invited to extend study participation without treatment, until study termination in October 2009. Patients were excluded if they had an AFP > 200 ng / ml or a suspicious mass on any abdominal imaging at the time of enrollment. Patients underwent prospective evaluation every 6 to 12 months by physical examination, ultrasound, and AFP. Patients with an elevated or rising AFP and those with new lesions on ultrasound were evaluated with computed tomography or magnetic resonance imaging. Defi nite HCC was defi ned by (a) imaging demonstrating a mass with AFP levels > 1,000 ng / ml or (b) histologic confi rmation. In the absence of histology or AFP < 1,000 ng / ml, presumed HCC was defi ned as a new mass on ultrasound with one of the following characteristics: (a) two imaging studies with characteristic fi ndings of HCC, (b) progressively enlarging lesion on ultrasound leading to patient death, (c) one imaging study demonstrating an enlarging mass with characteristics of HCC, or (d) one imaging study demonstrating a mass and increasing AFP levels. An Outcomes Review Panel, comprised of a rotating panel with three trial investigators, adjudicated all diagnoses of presumed and defi nite HCC. At the time of the initial HALT-C model development (median follow-up of 4.6 years), 48 patients had developed HCC ( 16 ) . At the time of this study (median follow-up 5.7 years), an additional 40 patients had developed HCC ( 15 ) .
Assessing and comparing model performance
We compared the performance of the machine-learning algorithm and UM regression model with that of the previously published model from the HALT-C Trial ( 16 ): age * 0.049 + black race * 0.712 + alkaline phosphatase * 0.006 + esophageal varices * 0.777 + ever smoked * 0.749 -platelets * 0.011. Th e UM regression model was validated using data from the HALT-C cohort, and the HALT-C model was validated using the UM cohort data. Machine-learning algorithms do not need crossvalidation or a separate validation set to get an unbiased estimate of error for machine learning algorithms, as it is estimated internally using the out-of-bag estimates ( 14 ). However, we penalized our analysis against the machine-learning model by still performing both out-of-bag internal validation in the UM cohort as well as external validation in the HALT-C cohort. We used several complementary methods to assess diff erent aspects of model performance. We fi rst compared model discrimination for the regression models and machine-learning algorithms using receiver operating characteristic curve analysis. Th e gain in diagnostic accuracy was then assessed with the net reclassifi cation improvement statistic (NRI), using the Youden model ( 18 ), and the integrated discrimination improvement (IDI) statistic; risk thresholds in the machine learning algorithm model were obtained to maximize sensitivity in order to capture all patients with HCC. Using risk cut-off s to defi ne a low-risk and high-risk group, we assessed the ability of each model to diff erentiate the risk of HCC development among low-risk and high-risk patients. Finally, we assessed the performance of each model using Brier scores and HosmerLemeshow χ 2 goodness-of-fi t test ( Supple mentary Material ). Analyses were conducted using STATA statistical soft ware 11.2 (College Station, TX) and R statistical package 2.14.0 ( 19 ) .
RESULTS
University of Michigan study population
Th e UM cohort consisted of 442 patients with cirrhosis but without prevalent HCC. Baseline characteristics of the patients are shown in Table 1 . Th e median age of the patients was 52.8 years (range 23.6 -82.4). More than 90 % of the patients were Caucasian and 58.6 % were men. Th e most common etiologies of cirrhosis were hepatitis C (47.3 % ), cryptogenic (19.2 % ), and alcoholinduced liver disease (14.5 % ). A total of 42.9 % patients were Child Pugh class A and 52.5 % were Child Pugh class B. Median Child Pugh and MELD scores at enrollment were 7 and 9, respectively. Median baseline AFP level was 5.9 ng / ml in patients who developed HCC, and 3.7 ng / ml in patients who did not develop HCC during follow-up ( P < 0.01). Median follow-up of the cohort was 3.5 years (range 0 -6.6), with at least 1 year of follow-up in 392 (88.7 % ) patients. Over a 1454 person-year follow-up period, 41 patients developed HCC for an annual incidence of 2.8 % ( Figure 1 ) . Th e cumulative 3-and 5-year probability of HCC development was 5.7 and 9.1 % , respectively. Of the 41 patients with HCC, 4 (9.8 % ) tumors were classifi ed as very early stage (BCLC stage 0) and 19 (46.3 % ) as BCLC stage A.
HALT-C trial study population
Th e HALT-C cohort consisted of 1050 patients, with a mean age of 49 years and 71 % being male. Cirrhosis was present at baseline in 41 % of patients, with all cirrhotic patients having Child-Pugh A disease. Th e mean baseline platelet count was 159 
UM regression model for HCC development
In the UM cohort, the following baseline variables were shown to be associated with the development of HCC with P < 0.10 on univariate analysis: AFP level ( P < 0.001), bilirubin ( P = 0.02), male gender ( P = 0.03), aspartate aminotransferase ( P = 0.03), alanine aminotransferase ( P = 0.03), Child Pugh score ( P = 0.05), and viral etiology ( P = 0.07). We also entered variables determined to be clinically relevant a priori into the multivariate regression model: patient age, body mass index, and presence of diabetes. On multivariate analysis, baseline AFP level (hazard ratio (HR) 1.01, 95 % confi dence interval (CI) 1.00 -1.02) and male gender (HR 2.25, 95 % CI 1.08 -4.70) were independent predictors of HCC development.
Machine-learning algorithm models for HCC development
Random forest algorithms using baseline variables including patient demographics, clinical data, and laboratory values were used to identify patients who developed HCC in the UM cohort. Th e proportional importance of each input variable in the random forest model is shown in Figure 2 . Th e most important independent variables in diff erentiating patients who developed HCC and those without HCC were as follows: aspartate aminotransferase, alanine aminotransferase, the presence of ascites, bilirubin, baseline AFP level, and albumin.
Performance of risk stratifi cation models in the derivation cohorts
Th e machine-learning algorithm and UM regression model were derived using data from the UM cohort, whereas the previously derived HALT-C model was assessed in the fi nal HALT-C cohort. Th e performance characteristics of the models are detailed in Table 2 . Th e HALT-C model had a sensitivity of 70.7 % and specifi city of 41.6 % to identify HCC patients in the UM cohort, using the previously published cutoff of 3.25 for high-risk patients. Th e UM regression model was able to achieve a sensitivity of 92.0 % but only had a specifi city of 15.7 % in the HALT-C cohort. Th e machine-learning algorithm was able to achieve a high sensitivity, correctly identifying 71 (80.7 % ) of the 88 patients who developed HCC, while still maintaining a specifi city of 46.8 % . It also had signifi cantly better diagnostic accuracy than the UM regression model and HALT-C model when validated (integrated discrimination improvement = 0.01, P = 0.04; net reclassifi cation improvement = 0.39, P < 0.001).
DISCUSSION
HCC surveillance is currently recommended for all patients with cirrhosis, regardless of other risk factors, to detect tumors at a scores and Hosmer -Lemeshow results are found in Supplementary Material .
Another critical issue for clinical application of a new algorithm is the proportion of patients correctly classifi ed ( Table 3 ) . Using the previously published cutoff of 3.25 to identify high-risk patients, the HALT-C model had a sensitivity and specifi city of 40.9 and 85.4 % in the fi nal HALT-C cohort. Th e UM regression model achieved a sensitivity and specifi city of 53.7 and 66.6 % , whereas the machine-learning algorithm had a sensitivity and specifi city of 80.5 and 57.9 % in the UM cohort.
Performance of risk stratifi cation models in the validation cohorts
Validation of the HALT-C model was performed using data from the UM cohort, whereas the regression model and machine-learning algorithm were validated using HALT-C cohort data. potentially curative stage and thereby reduce mortality. However, the risk of developing HCC is likely not uniform across all patients. We compared the predictive ability of three models, two using traditional regression techniques and the other using novel machine-learning algorithms, to identify a subset of cirrhotic patients at high risk for HCC. Th e machine-learning algorithm model outperformed both the UM regression model and the previously published HALT-C model, had the best predictive ability to identify patients at high risk for HCC, and may be used to risk stratify patients with regard to their risk of HCC development. Although prior studies have developed predictive models for HCC, our study is the fi rst to externally validate our predictive models. Validation is an important aspect of predictive model development, given the performance of regression models is generally substantially higher in derivation datasets than validation sets ( 20 ) . Th e importance of validation is highlighted in our study, as the previously published HALT-C model performed better in the HALT-C cohort than the UM cohort. Th is diff erence in performance is likely driven by several key diff erences in study populations. Th e HALT-C cohort included only hepatitis C virus patients and 59 % of patients had advanced fi brosis without cirrhosis. In contrast, the UM cohort included patients of various etiologies (49 % non-viral) and all had underlying cirrhosis, including 52 % with Child Pugh B disease. Given the marked heterogeneity among at-risk populations in terms of etiologies of liver disease, degree of liver dysfunction, and prevalence of other risk factors (such as diabetes, smoking or alcohol use), validation of any predictive model for HCC development is crucial.
Our machine-learning algorithm model demonstrated significantly better diagnostic accuracy compared with models derived using traditional regression techniques. Although there was only a trend toward a higher c-statistic, it was able to classify patients with signifi cantly better accuracy, as demonstrated by the net reclassifi cation improvement and integrated discrimination improvement statistics. Receiver operating characteristic analysis alone is oft en insensitive for comparing predictive models ( 21, 22 ) ; therefore, methods including NRI and IDI have been proposed as better measures to compare risk stratifi cation models ( 22, 23 ) . Receiver operating characteristic curves are helpful in diagnostic settings, as the outcome is determined and can be compared to a gold standard; whereas in prognostic models, the outcome has not yet developed at the time of prediction, hence there is a component of randomness to the outcome. In predictive models, a c-statistic describes how well the model can rank-order cases and non-cases but it is not a function of actual predicted probabilities or the probability of the individual being classifi ed correctly. Th is makes it a less accurate measure of the prediction error. Our paper highlights the importance of using novel risk prediction performance measures to accurately provide risk predictions with little change in the c-statistic.
Machine-learning algorithms also have several other advantages over traditional statistical modeling. Machine learning algorithms consider all potential interactions and lack a predefi ned hypothesis, making it less likely to overlook unexpected predictor variables ( 8 ) . Predictive models using machine-learning algorithms may therefore facilitate recognition of clinically important risk among patients with several marginal risk factors that may otherwise not raise clinical concerns. Furthermore, machine learning algorithms can easily incorporate new clinical data to continually update and optimize algorithms with minimal oversight ( 8 ) . For example, a machinelearning algorithm to predict response to thiopurines in patients with infl ammatory bowel disease has been successfully used as a decision support tool aft er it was shown to outperform metabolite testing ( 24 ) . If further refi ned to have better accuracy, machinelearning algorithms could be used as the basis for an electronic health record decision support tool to aid providers with real-time assessments of HCC risk and recommendations regarding HCC surveillance. Implementation of the predictive algorithm could be used to identify high-risk individual cases and transmit annotated data back to the provider, facilitating changes to their clinical assessment. If prospectively validated, machine-learning algorithms could also form the basis for a publicly available online HCC risk calculator.
Accurate assessment of HCC risk among patients with cirrhosis may allow targeted application of HCC surveillance programs, HALT-C, Hepatitis C Antiviral Long-term Treatment against Cirrhosis; HCC, hepato cellular carcinoma. a The machine-learning algorithm and UM regression model were derived using data from the UM cohort, whereas the HALT-C model was derived in the HALT-C cohort. Validation of the machine-learning algorithm and UM regression model was performed using the HALT-C cohort data, and HALT-C model using UM cohort data. b Risk score cutoffs, derived to maximize overall model accuracy, were used to defi ne a low-risk and high-risk group for each model. The machine-learning algorithm used an out-of-bag sample from the derivation dataset to obtain the cutoff, whereas a cross-validation model was used to derive the cutoff for the UM regression model.
given that HCC surveillance is only cost-eff ective among those with an annual HCC risk of > 1.5 % ( 25 ). Although low-risk patients still have some risk of developing HCC, the annual risk may be < 1.5 % and surveillance may not be cost-eff ective in this cohort. Similarly, patients in the high-risk cohort may benefi t from a more intensive HCC surveillance regimen given the suboptimal eff ectiveness of ultrasound to fi nd tumors at an early stage ( 11, 17 ) . Although surveillance with cross-sectional imaging is not recommended among all patients with cirrhosis, it is possible that this would be costeff ective among a subgroup of cirrhotic patients.
Although the machine learning algorithm outperformed traditional regression modeling, both models only have moderate accuracy for the prediction of HCC development. It is possible, if not likely, that readily available clinical variables, such as demographics and liver function, only partially account for HCC risk among patients with cirrhosis. Th e addition of biomarkers or genetic markers may be necessary to further improve HCC risk prognostication.
We identifi ed variables associated with HCC development, including male gender and baseline AFP level. Since the release of the 2010 American Association for the Study of Liver Disease guidelines, there has been extensive debate regarding the utility of AFP in clinical practice ( 11,17,25 -28 ) . Our study highlights that AFP may be useful in risk stratifi cation in patients with cirrhosis. Even though baseline AFP levels were low for both patients with and without HCC, we found that baseline AFP was one of the most important predictors for HCC in both the regression model and machinelearning algorithm. Th erefore, we believe that continued AFP testing could have an important role among patients with cirrhosis in terms of prognostication, if not actual screening, in clinical practice.
It is important to note that our study had several limitations. Our study was performed in a single tertiary care center and may not be generalized to other practice settings. Second, ~ 18 % of the patients were lost to follow-up, although the median follow-up for these patients was 2.8 years and their survival status was verifi ed through the social security death fi le. Further, these patients had lessadvanced cirrhosis (lower Child Pugh class and MELD scores) and were less likely to develop hepatic decompensation, HCC, or death. Finally, our machine learning algorithm had suboptimal accuracy in the validation cohort. Although promising, further refi nement of the machine-learning algorithm is still necessary before routine use in clinical practice. Overall, we believe that the limitations of this study are outweighed by its notable strengths including its prospective enrollment with adjudication of HCC outcomes, its novel methodology, and the validation of our models in independent cohorts.
In conclusion, we present the fi rst externally validated model for HCC risk prediction, which appears to outperform previously published models. Th e use of machine learning algorithms signifi cantly improved predictive ability compared with traditional regression analysis; however, the addition of novel biomarkers and / or longitudinal data may still allow further refi nement. We found that predictive models using readily available clinical data can accurately identify cirrhotic patients at high risk for HCC development. Studies to determine whether these models could prospectively risk stratify patients with cirrhosis regarding their risk of HCC development should be performed.
